Results 81 to 90 of about 11,301 (165)

Safety and efficacy of PCSK9 inhibitors and effect on coronary plaque phenotype in statin-treated patients following acute coronary syndrome: a systematic review and meta-analysis

The Egyptian Heart Journal
Background Acute coronary syndrome continues to be a significant cardiovascular issue. Statins are commonly acknowledged as medications that reduce LDL-C levels and stabilize plaques. Nevertheless, their efficacy is limited.
Dennis Ievan Hakim, Faqrizal Ria Qhabibi, Muhammad Yusuf, Nasim Amar, Indra Prasetya, Ade Meidian Ambari   +5 more
doaj   +1 more source

Pulmonary Vascular Endothelial Cells in Lung Diseases: Mechanisms, Therapeutic Strategies, and Future Directions

Cell Proliferation, Volume 59, Issue 2, February 2026.
The pathogenic mechanisms of pulmonary vascular endothelial cells (VECs) in lung diseases and their multimodal therapeutic strategies. ABSTRACT Pulmonary vascular endothelial cells (VECs) are essential for the normal function of the lung, through maintaining vascular barrier integrity, regulating blood flow, and participating in inflammatory responses ...
Qianyue Liu, Hongshuai Zheng, Jing Liu, Ming Gao, Faquan Lin, Lin Liao   +5 more
wiley   +1 more source

Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study)

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 906-913, February 2026.
Abstract Aims To evaluate the lipid‐lowering efficacy, safety, and adherence of switching from moderate‐ or low‐intensity statin monotherapy to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus (T2DM) and dyslipidaemia.
Sangmo Hong, Won J. Kim, Sungrae Kim, Jung H. Park, Eun S. Kang, Min K. Moon, Jae T. Kim, Ji‐Oh Mok, Ki Y. Lee, Cheol‐Young Park, Chang B. Lee   +10 more
wiley   +1 more source

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025

Medical Journal of Australia, Volume 224, Issue 2, February 2026.
ABSTRACT Introduction The Australian clinical guideline for diagnosing and managing acute coronary syndromes 2025 establishes a new clinical standard for the diagnosis and management of acute coronary syndromes (ACS) in Australia. The new guideline replaces the 2016 guideline, representing the first major update in nearly a decade.
David B. Brieger, Louise A. Cullen, Tom G. Briffa, Sarah Zaman, Ian A. Scott, Cynthia Papendick, Elaine Ho, Victoria Leitch, Dannii Dougherty, Garry Jennings   +9 more
wiley   +1 more source

PCSK9 inhibition: from effectiveness to cost-effectiveness

Frontiers in Cardiovascular Medicine
Dyslipidaemia is a complex disorder characterised by abnormal lipid levels in the blood, including cholesterol and triglycerides, and plays an important role in the development of atherosclerotic cardiovascular disease.
Iveta Mercep, Iveta Mercep, Dominik Strikic, Pero Hrabac, Ivan Pecin, Željko Reiner, Željko Reiner   +6 more
doaj   +1 more source

New lipid therapies: PCSK9 inhibitors

Journal of Clinical and Translational Endocrinology: Case Reports, 2016
AbstractPharmacologic therapy reduces cardiovascular risk in a variety of primary and secondary prevention clinical situations in addition to lifestyle modifications. Low density lipoprotein cholesterol (LDL-C) is a key mediator of atherogenesis. Most cholesterol guidelines propose specific LDL-C while recently the ACC/AHA recommends statin therapy ...
Farah Meah, DO, Arshi Basit, MD, Alaleh Mazhari, DO, Mary Ann Emanuele, MD, Nicholas Emanuele, MD   +4 more
openaire   +2 more sources

PCSK9 Inhibitors

Journal of the American College of Cardiology, 2017
Mark A. Hlatky, Dhruv S. Kazi
openaire   +2 more sources

Therapeutic Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Althea Medical Journal
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a novel class of medications for managing dyslipidemia. Although previous meta-analyses have confirmed their efficacy in lowering low-density lipoprotein cholesterol ...
Nur Hafidha Hikmayani, Ratih Puspita Febrinasari, Ariq Ratya Satwika   +2 more
doaj   +1 more source

PCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report

Frontiers in Cardiovascular Medicine
BackgroundApproximately 3.8 million patients in China suffer from familial hypercholesterolemia (FH). Statins and PCSK9 inhibitors are recommended by guidelines as therapeutic agents.
Yuan Li, Huiyan Jiang, Yajuan Xiong, Simin Yan, Xin Chen   +4 more
doaj   +1 more source

Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders

Vascular Health and Risk Management, 2016
Sanjiv Gupta Department of Interventional Cardiology, Santokba Durlabhji Memorial Hospital Cum Medical Research Institute, Jaipur, India Abstract: The aim of this manuscript is to review available data to evaluate the present status of proprotein ...
Gupta S
doaj